IM Cannabis Corp. Welcomes Shmulik Arbel to Its Board of Directors
IM Cannabis Corp. (NASDAQ: IMCC) is pleased to announce that Shmulik Arbel has officially joined its Board of Directors. This important move is part of the company’s strategy to bolster its governance and support its growth initiatives.
Shmulik Arbel's Background in Banking and Finance
Arbel brings a wealth of experience from his former position at Leumi, one of the largest banks, where he served as Deputy CEO until recently. His diverse background in banking and finance is set to support IM Cannabis’ dedication to achieving sustainable and profitable growth in a competitive cannabis marketplace.
Leadership Comments
Oren Shuster, the CEO of IM Cannabis, shared his excitement about Arbel’s addition to the board, stating, “We’re thrilled to welcome Shmulik to our Board of Directors. His extensive international experience and proven track record will be invaluable as we pursue our strategic initiatives.” Arbel's expertise in banking is expected to significantly enhance the company's performance moving forward.
Arbel's Vision for IM Cannabis
Upon his appointment to the board, Arbel expressed, “I’m honored to be part of IM Cannabis. I look forward to using my banking and finance expertise to strengthen the company’s position in the global cannabis market and contribute to its growth.” His insights are expected to offer valuable guidance as the company expands its global presence.
About IM Cannabis Corp.
IM Cannabis Corp. is recognized as a key player in the international medical cannabis market, dedicated to providing high-quality products to patients across various regions. With a strong focus on Israel and Germany, IM Cannabis is committed to sustainable growth through a unique data-driven approach. The company operates within a robust ecosystem that includes distribution centers and retail pharmacies, ensuring quality and safety throughout its supply chain.
In Germany, IM Cannabis works in collaboration with Adjupharm GmbH, which enhances its capability to distribute medical cannabis. This strategic partnership aims to improve access to premium cannabis products while adhering to the highest standards of compliance.
Growth and Business Strategy
With Shmulik Arbel’s recent appointment, IM Cannabis is set to reinforce its presence in major markets. The company’s strategy emphasizes responsible growth, compliance, and leveraging insights drawn from data collected over the years. This proactive approach aims to improve IM Cannabis' brand and operational effectiveness, positioning it as a distinguished player in the cannabis industry.
Company Contact
For further information, feel free to reach out to the contacts below:
Anna Taranko
Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
a.taranko@imcannabis.de
Oren Shuster
CEO
IM Cannabis Corp.
info@imcannabis.com
Frequently Asked Questions
What is IM Cannabis Corp.?
IM Cannabis Corp. stands out as a leading international company in the medical cannabis sector, focusing on delivering top-quality cannabis products.
Who is Shmulik Arbel?
Shmulik Arbel is the newly appointed member of the Board of Directors at IM Cannabis, bringing extensive experience from the banking and finance sectors.
Why is Shmulik Arbel's appointment significant?
His experience is expected to enhance the company’s governance and drive profitable growth in key strategic markets.
What markets does IM Cannabis focus on?
The company’s primary focus is on medical cannabis markets in Germany and Israel.
How can I contact IM Cannabis for more information?
If you need more information, you can contact Anna Taranko or Oren Shuster using the email addresses provided for investor inquiries.
